57 related articles for article (PubMed ID: 22593467)
1. Patient age and biological aggressiveness of endometrial carcinoma.
Gonzalez-Rodilla I; Boix M; Verna V; Muñoz AB; Estévez J; Jubete Y; Schneider J
Anticancer Res; 2012 May; 32(5):1817-20. PubMed ID: 22593467
[TBL] [Abstract][Full Text] [Related]
2. Expression of the apoptosis-related genes Bcl-2 and p53 in clinical samples from endometrial carcinoma patients.
González-Rodilla I; Verna V; Muñoz AB; Estévez J; Boix M; Schneider J
Anticancer Res; 2011 Dec; 31(12):4191-3. PubMed ID: 22199279
[TBL] [Abstract][Full Text] [Related]
3. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J
Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154
[TBL] [Abstract][Full Text] [Related]
4. Assessment of inhibin and p53 in granulosa cell tumors of the ovary.
Gebhart JB; Roche PC; Keeney GL; Lesnick TG; Podratz KC
Gynecol Oncol; 2000 May; 77(2):232-6. PubMed ID: 10785470
[TBL] [Abstract][Full Text] [Related]
5. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
6. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
7. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
9. p53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer.
Seeger A; Kölbl H; Petry IB; Gebhard S; Battista MJ; Böhm D; Steiner E
Gynecol Oncol; 2012 Apr; 125(1):200-7. PubMed ID: 22210468
[TBL] [Abstract][Full Text] [Related]
10. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
[TBL] [Abstract][Full Text] [Related]
11. [Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma].
Frutuoso C; Silva MR; Amaral N; Martins I; De Oliveira C; De Oliveira HM
Acta Med Port; 2001; 14(3):277-83. PubMed ID: 11552325
[TBL] [Abstract][Full Text] [Related]
12. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma.
Yi TZ; Guo J; Zhou L; Chen X; Mi RR; Qu QX; Zheng JH; Zhai L
Cancer Invest; 2011 Jan; 29(1):86-92. PubMed ID: 20874004
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma.
Caduff RF; Johnston CM; Svoboda-Newman SM; Poy EL; Merajver SD; Frank TS
Am J Pathol; 1996 May; 148(5):1671-8. PubMed ID: 8623934
[TBL] [Abstract][Full Text] [Related]
15. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
Salvesen HB; Das S; Akslen LA
Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53 overexpression in endometrial cancer.
Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
Cancer Res; 1994 Sep; 54(17):4667-70. PubMed ID: 8062261
[TBL] [Abstract][Full Text] [Related]
18. [A study on expression of tumor suppressor gene p53 in endometrial carcinoma].
Xue F; Jiao S; Zhao F
Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):647-50. PubMed ID: 8745486
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
20. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
